DTX3L was originally identified as a binding partner of ARTD9 and as a novel risk-related gene product in high-risk chemotherapy-resistant aggressive forms of DLBCL [469, 542]. The gene discussed is PARP9; the disease is diffuse large B-cell lymphoma.